Lisuride in Parkinson's disease. 4-Year follow-up

P. Giovannini; G. Scigliano; I. Piccolo; P. Soliveri; I. Scuhy; T. Caraceni

Lisuride in Parkinson's disease. 4-Year follow-up

P. Giovannini, G. Scigliano, I. Piccolo, P. Soliveri, I. Scuhy, T. Caraceni

Fondazione IRCCS Istituto Neurologico "C. Besta"

Research output: Contribution to journal › Article › peer-review

Abstract

Lisuride at a mean daily dose of 3 mg was given to 48 patients with idiopathic Parkinson's disease. Twenty received lisuride alone (Group A) and 36 received lisuride + L-Dopa + peripheral decarboxylase inhibitors (Group B). Dropouts were due primarily to lack of efficacy in Group A patients and to mental side effects in Group B patients. The patients who remained in the study for the full 4 years showed distinct improvement, which was maintained. Group A patients did not have the on-off phenomenon or abnormal involuntary movements.

Original language	English
Pages (from-to)	201-211
Number of pages	11
Journal	Clinical Neuropharmacology
Volume	11
Issue number	3
Publication status	Published - 1988

ASJC Scopus subject areas

Clinical Neurology
Pharmacology (medical)
Neuroscience(all)
Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{42305d982b104908ab25f8c71c3f9067,

title = "Lisuride in Parkinson's disease. 4-Year follow-up",

abstract = "Lisuride at a mean daily dose of 3 mg was given to 48 patients with idiopathic Parkinson's disease. Twenty received lisuride alone (Group A) and 36 received lisuride + L-Dopa + peripheral decarboxylase inhibitors (Group B). Dropouts were due primarily to lack of efficacy in Group A patients and to mental side effects in Group B patients. The patients who remained in the study for the full 4 years showed distinct improvement, which was maintained. Group A patients did not have the on-off phenomenon or abnormal involuntary movements.",

author = "P. Giovannini and G. Scigliano and I. Piccolo and P. Soliveri and I. Scuhy and T. Caraceni",

year = "1988",

language = "English",

volume = "11",

pages = "201--211",

journal = "Clinical Neuropharmacology",

issn = "0362-5664",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Lisuride in Parkinson's disease. 4-Year follow-up

AU - Giovannini, P.

AU - Scigliano, G.

AU - Piccolo, I.

AU - Soliveri, P.

AU - Scuhy, I.

AU - Caraceni, T.

PY - 1988

Y1 - 1988

N2 - Lisuride at a mean daily dose of 3 mg was given to 48 patients with idiopathic Parkinson's disease. Twenty received lisuride alone (Group A) and 36 received lisuride + L-Dopa + peripheral decarboxylase inhibitors (Group B). Dropouts were due primarily to lack of efficacy in Group A patients and to mental side effects in Group B patients. The patients who remained in the study for the full 4 years showed distinct improvement, which was maintained. Group A patients did not have the on-off phenomenon or abnormal involuntary movements.

AB - Lisuride at a mean daily dose of 3 mg was given to 48 patients with idiopathic Parkinson's disease. Twenty received lisuride alone (Group A) and 36 received lisuride + L-Dopa + peripheral decarboxylase inhibitors (Group B). Dropouts were due primarily to lack of efficacy in Group A patients and to mental side effects in Group B patients. The patients who remained in the study for the full 4 years showed distinct improvement, which was maintained. Group A patients did not have the on-off phenomenon or abnormal involuntary movements.

UR - http://www.scopus.com/inward/record.url?scp=0023907407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023907407&partnerID=8YFLogxK

M3 - Article

C2 - 3401856

AN - SCOPUS:0023907407

VL - 11

SP - 201

EP - 211

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 3

ER -

Lisuride in Parkinson's disease. 4-Year follow-up

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this